Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.61 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013416 | 0.89 | HCRTR1 (0.60) | HCRTR1HCRTR2NPC1RAB9AHTR1A | |
| SCHEMBL2012310 | 0.87 | HCRTR1 (0.67) | HCRTR1HCRTR2NPC1RAB9AHTR1A | |
| SCHEMBL2013516 | 0.86 | HCRTR1 (0.66) | HCRTR1HCRTR2NPC1RAB9ACCR1 | |
| SCHEMBL6918071 | 0.86 | HCRTR1 (0.66) | HCRTR1HCRTR2NPC1RAB9ACCR1 | |
| SCHEMBL2015027 | 0.85 | HCRTR1 (0.56) | HCRTR1HCRTR2NPC1RAB9AHRH3 | |
| SCHEMBL2010539 | 0.84 | HCRTR1 (0.63) | HCRTR1HCRTR2NPC1RAB9AHRH3 | |
| SCHEMBL2017211 | 0.84 | HCRTR1 (0.59) | HCRTR1HCRTR2NPC1RAB9AHRH3 | |
| SCHEMBL2019129 | 0.84 | HCRTR1 (0.59) | HCRTR1HCRTR2NPC1RAB9AHRH3 | |
| SCHEMBL2016643 | 0.83 | HCRTR1 (0.56) | HCRTR1HCRTR2NPC1RAB9AHRH3 | |
| SCHEMBL13139060 | 0.83 | HCRTR1 (0.77) | HCRTR1HCRTR2NPC1RAB9AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |